Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Assets start week on strong note; Polish zloty up after presidential results

07/13/2020 | 04:47am EDT

* Poland's incumbent Duda wins presidential election

* Investors eye start of U.S. earnings season

* Turkish industrial production shrinks less-than-expected in May

July 13 (Reuters) - Emerging market risk assets started the week on a strong footing on Monday, with investors turning their focus towards the beginning of the U.S. corporate earnings season, while Poland's zloty edged higher after Andrzej Duda won the country's presidential election.

Market participants are optimistic that U.S. companies will beat already lowered expectations, with big banks JPMorgan , Citigroup, and Wells Fargo reporting on Tuesday.

"I expect that trading revenues will outperform once again as market volatility continues," said Jeffrey Halley, senior market analyst, Asia Pacific at OANDA.

"More attention is likely to be given to the big banks' forward guidance on the global economy, and the level of bad debt provisioning."

Assets in emerging markets have risen sharply since a selloff in March, but have remained in a holding pattern for the last couple weeks due to a lack of market drivers and caution over the rising number of COVID-19 cases worldwide.

Analysts also suggest that monetary policy, which was a key driver of the market recovery so far, will gradually lose influence to the earnings outlook.

MSCI's index for emerging market stocks rose 0.7%, while its currencies counterpart index gained 0.1%.

Shares in the developing world also got a boost from a positive reading on a potential COVID-19 treatment as an analysis from Gilead Sciences Inc on Friday showed its antiviral remdesivir helped reduce the risk of death in severely ill patients.

In Poland, incumbent candidate Andrzej Duda won the presidential election, according to majority results, the National Electoral Commission said on Monday. The zloty made small gains against the dollar, while Polish stocks rose 0.6%.

"With Duda holding on to power, Polish politics will retain its status quo for now – the prospect of a new era in politics is receding. For the zloty, this outcome is relatively positive as the market tends to prefer continuity over uncertainty," said Tatha Ghose, FX and emerging markets analyst at Commerzbank.

Among other emerging market currencies including the Russian rouble, Turkish lira and South Africa's rand , all rose against a weaker dollar.

Data from Turkey showed some signs of relief as industrial production shrank less-than-expected in May.

For GRAPHIC on emerging market FX performance in 2020, see http://tmsnrt.rs/2egbfVh For GRAPHIC on MSCI emerging index performance in 2020, see https://tmsnrt.rs/2OusNdX

For TOP NEWS across emerging markets

For CENTRAL EUROPE market report, see

For TURKISH market report, see

For RUSSIAN market report, see (Reporting by Shreyashi Sanyal in Bengaluru; Editing by Shailesh Kuber)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CITIGROUP INC. -0.33% 66.71 Delayed Quote.8.19%
COMMERZBANK AG -0.04% 5.448 Delayed Quote.3.46%
EURO / POLISH ZLOTY NEW (EUR/PLN) 0.18% 4.569 Delayed Quote.0.48%
GILEAD SCIENCES, INC. 0.54% 69.02 Delayed Quote.18.47%
JPMORGAN CHASE & CO. -0.19% 150.64 Delayed Quote.18.78%
US DOLLAR / POLISH ZLOTY NEW (USD/PLN) 0.00% 3.8806 Delayed Quote.4.13%
US DOLLAR / TURKISH LIRA (USD/TRY) 0.00% 8.5471 Delayed Quote.15.12%
WELLS FARGO & COMPANY -0.98% 44.59 Delayed Quote.47.75%
All news about GILEAD SCIENCES, INC.
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
07/20ARCUS BIOSCIENCES : Chief Medical Officer Resigns to Join Gilead's Oncology Team
07/20PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
07/19ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
07/19Health Care Down Amid Defensive Bias -- Health Care Roundup
07/19GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
07/19BIONTECH : to Buy Neoantigen TCR Cell Therapy Platform, Facility from Gilead's K..
More news
Financials (USD)
Sales 2021 24 674 M - -
Net income 2021 6 917 M - -
Net Debt 2021 21 985 M - -
P/E ratio 2021 13,1x
Yield 2021 4,09%
Capitalization 86 563 M 86 563 M -
EV / Sales 2021 4,40x
EV / Sales 2022 4,35x
Nbr of Employees 13 600
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 69,02 $
Average target price 75,07 $
Spread / Average Target 8,76%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.37.17%71 226
BIONTECH SE244.68%55 555
BEIGENE, LTD.24.51%33 627